vs
ExlService Holdings, Inc.（EXLS）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是ExlService Holdings, Inc.的1.9倍（$1.0B vs $542.6M），豪洛捷净利率更高（17.1% vs 11.1%，领先6.0%），ExlService Holdings, Inc.同比增速更快（12.7% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $106.5M），过去两年ExlService Holdings, Inc.的营收复合增速更高（11.5% vs 1.5%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
EXLS vs HOLX — 直观对比
营收规模更大
HOLX
是对方的1.9倍
$542.6M
营收增速更快
EXLS
高出10.2%
2.5%
净利率更高
HOLX
高出6.0%
11.1%
自由现金流更多
HOLX
多$108.7M
$106.5M
两年增速更快
EXLS
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $1.0B |
| 净利润 | $60.2M | $179.1M |
| 毛利率 | 38.6% | 56.0% |
| 营业利润率 | 14.4% | 22.6% |
| 净利率 | 11.1% | 17.1% |
| 营收同比 | 12.7% | 2.5% |
| 净利润同比 | 18.9% | -10.9% |
| 每股收益（稀释后） | $0.38 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSHOLX
| Q4 25 | $542.6M | $1.0B | ||
| Q3 25 | $529.6M | $1.0B | ||
| Q2 25 | $514.5M | $1.0B | ||
| Q1 25 | $501.0M | $1.0B | ||
| Q4 24 | $481.4M | $1.0B | ||
| Q3 24 | $472.1M | $988.0M | ||
| Q2 24 | $448.4M | $1.0B | ||
| Q1 24 | $436.5M | $1.0B |
净利润EXLSHOLX
| Q4 25 | $60.2M | $179.1M | ||
| Q3 25 | $58.2M | $187.2M | ||
| Q2 25 | $66.1M | $194.9M | ||
| Q1 25 | $66.6M | $-17.4M | ||
| Q4 24 | $50.7M | $201.0M | ||
| Q3 24 | $53.0M | $178.6M | ||
| Q2 24 | $45.8M | $194.5M | ||
| Q1 24 | $48.8M | $169.9M |
毛利率EXLSHOLX
| Q4 25 | 38.6% | 56.0% | ||
| Q3 25 | 38.5% | 55.6% | ||
| Q2 25 | 37.7% | 56.3% | ||
| Q1 25 | 38.6% | 37.5% | ||
| Q4 24 | 38.1% | 56.8% | ||
| Q3 24 | 37.8% | 56.4% | ||
| Q2 24 | 37.1% | 55.4% | ||
| Q1 24 | 37.4% | 53.3% |
营业利润率EXLSHOLX
| Q4 25 | 14.4% | 22.6% | ||
| Q3 25 | 14.4% | 22.6% | ||
| Q2 25 | 15.8% | 24.9% | ||
| Q1 25 | 15.7% | -0.7% | ||
| Q4 24 | 14.8% | 22.5% | ||
| Q3 24 | 14.7% | 23.3% | ||
| Q2 24 | 13.7% | 24.1% | ||
| Q1 24 | 14.1% | 20.7% |
净利率EXLSHOLX
| Q4 25 | 11.1% | 17.1% | ||
| Q3 25 | 11.0% | 17.8% | ||
| Q2 25 | 12.8% | 19.0% | ||
| Q1 25 | 13.3% | -1.7% | ||
| Q4 24 | 10.5% | 19.7% | ||
| Q3 24 | 11.2% | 18.1% | ||
| Q2 24 | 10.2% | 19.2% | ||
| Q1 24 | 11.2% | 16.7% |
每股收益（稀释后）EXLSHOLX
| Q4 25 | $0.38 | $0.79 | ||
| Q3 25 | $0.36 | $0.84 | ||
| Q2 25 | $0.40 | $0.86 | ||
| Q1 25 | $0.40 | $-0.08 | ||
| Q4 24 | $0.31 | $0.87 | ||
| Q3 24 | $0.33 | $0.75 | ||
| Q2 24 | $0.28 | $0.82 | ||
| Q1 24 | $0.29 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $2.4B |
| 总债务越低越好 | $298.6M | $2.5B |
| 股东权益账面价值 | $912.7M | $5.2B |
| 总资产 | $1.7B | $9.2B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资EXLSHOLX
| Q4 25 | $328.4M | $2.4B | ||
| Q3 25 | $390.1M | $2.2B | ||
| Q2 25 | $353.3M | $1.9B | ||
| Q1 25 | $331.4M | $1.6B | ||
| Q4 24 | $340.6M | $2.0B | ||
| Q3 24 | $325.8M | $2.3B | ||
| Q2 24 | $276.1M | $2.4B | ||
| Q1 24 | $246.2M | $2.2B |
总债务EXLSHOLX
| Q4 25 | $298.6M | $2.5B | ||
| Q3 25 | $354.8M | $2.5B | ||
| Q2 25 | $260.0M | $2.5B | ||
| Q1 25 | $307.3M | $2.5B | ||
| Q4 24 | $288.5M | $2.5B | ||
| Q3 24 | $344.7M | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
股东权益EXLSHOLX
| Q4 25 | $912.7M | $5.2B | ||
| Q3 25 | $952.4M | $5.0B | ||
| Q2 25 | $1.1B | $4.8B | ||
| Q1 25 | $1.0B | $4.6B | ||
| Q4 24 | $929.9M | $4.8B | ||
| Q3 24 | $907.6M | $5.1B | ||
| Q2 24 | $852.6M | $5.0B | ||
| Q1 24 | $803.3M | $4.8B |
总资产EXLSHOLX
| Q4 25 | $1.7B | $9.2B | ||
| Q3 25 | $1.7B | $9.0B | ||
| Q2 25 | $1.7B | $8.8B | ||
| Q1 25 | $1.7B | $8.5B | ||
| Q4 24 | $1.6B | $8.7B | ||
| Q3 24 | $1.6B | $9.2B | ||
| Q2 24 | $1.5B | $8.9B | ||
| Q1 24 | $1.4B | $8.7B |
负债/权益比EXLSHOLX
| Q4 25 | 0.33× | 0.48× | ||
| Q3 25 | 0.37× | 0.50× | ||
| Q2 25 | 0.25× | 0.52× | ||
| Q1 25 | 0.30× | 0.55× | ||
| Q4 24 | 0.31× | 0.53× | ||
| Q3 24 | 0.38× | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $215.2M |
| 自由现金流率自由现金流/营收 | 19.6% | 20.5% |
| 资本支出强度资本支出/营收 | 2.0% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.95× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $298.1M | $1.0B |
8季度趋势，按日历期对齐
经营现金流EXLSHOLX
| Q4 25 | $117.4M | $229.9M | ||
| Q3 25 | $120.7M | $355.1M | ||
| Q2 25 | $109.4M | $343.3M | ||
| Q1 25 | $3.2M | $169.4M | ||
| Q4 24 | $105.3M | $189.3M | ||
| Q3 24 | $110.1M | $367.0M | ||
| Q2 24 | $74.9M | $405.8M | ||
| Q1 24 | $-21.9M | $292.4M |
自由现金流EXLSHOLX
| Q4 25 | $106.5M | $215.2M | ||
| Q3 25 | $106.4M | $341.4M | ||
| Q2 25 | $95.0M | $330.5M | ||
| Q1 25 | $-9.7M | $153.9M | ||
| Q4 24 | $95.3M | $172.5M | ||
| Q3 24 | $97.3M | $350.6M | ||
| Q2 24 | $62.8M | $385.3M | ||
| Q1 24 | $-33.1M | $279.6M |
自由现金流率EXLSHOLX
| Q4 25 | 19.6% | 20.5% | ||
| Q3 25 | 20.1% | 32.5% | ||
| Q2 25 | 18.5% | 32.3% | ||
| Q1 25 | -1.9% | 15.3% | ||
| Q4 24 | 19.8% | 16.9% | ||
| Q3 24 | 20.6% | 35.5% | ||
| Q2 24 | 14.0% | 38.1% | ||
| Q1 24 | -7.6% | 27.5% |
资本支出强度EXLSHOLX
| Q4 25 | 2.0% | 1.4% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 2.8% | 1.3% | ||
| Q1 25 | 2.6% | 1.5% | ||
| Q4 24 | 2.1% | 1.6% | ||
| Q3 24 | 2.7% | 1.7% | ||
| Q2 24 | 2.7% | 2.0% | ||
| Q1 24 | 2.6% | 1.3% |
现金转化率EXLSHOLX
| Q4 25 | 1.95× | 1.28× | ||
| Q3 25 | 2.08× | 1.90× | ||
| Q2 25 | 1.66× | 1.76× | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 2.08× | 0.94× | ||
| Q3 24 | 2.08× | 2.05× | ||
| Q2 24 | 1.63× | 2.09× | ||
| Q1 24 | -0.45× | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
